康护乐小编今天带大家了解一下卢非酰胺这个药品

Eisai Corporation's North American subsidiary (Eisai Corporation) announced in November 2008 that the FDA had approved its rufinamide for the adjuvant treatment of Lennox-Gastaut syndrome (LGS). This product is suitable for children over 4 years old and adult patients. It is a triazole derivative whose compound structure is different from the anti-epileptic drugs currently on the market. It mainly works by regulating the voltage-gated sodium ion channels in the brain.

LGS is a type of refractory epilepsy in children characterized by recurring and frequent seizures. LGS accounts for approximately 4% of all childhood epilepsy cases, and affects approximately 300,000 children under the age of 14 in the United States. The first onset age of pediatric patients is generally 1 to 5 years old, and about 3% to 7% of pediatric patients die from the disease at an average age of less than 10 years.

Rufinamide is a new anti-epileptic drug of the triazole derivative class, which can limit nerve sodium ion-dependent action potentials and stabilize cell membranes. Studies have found that the highest daily dose of rufinamide (3200 mg) can effectively control the seizures of refractory partial-onset epilepsy and that most patients tolerate this dose well.

LGS is difficult to treat, and patients often need to take multiple anti-epileptic drugs to control seizures. The results of a double-blind, placebo-controlled study on the use of this product in the adjuvant treatment of LGS showed that the median frequency of generalized atonic seizures decreased by 42.5% in the this product group, while it increased by 1.4% in the placebo group. Studies also show that this product is well tolerated in pediatric patients.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.